134 related articles for article (PubMed ID: 23388840)
1. Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects.
Bouabdallah K; Ribrag V; Terriou L; Soria JC; Delarue R
Curr Opin Oncol; 2013 Mar; 25 Suppl 2():S1-12. PubMed ID: 23388840
[TBL] [Abstract][Full Text] [Related]
2. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
Hess G; Smith SM; Berkenblit A; Coiffier B
Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and management of temsirolimus in patients with relapsed or refractory mantle cell lymphoma.
Coiffier B
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):351-9. PubMed ID: 23763923
[TBL] [Abstract][Full Text] [Related]
4. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B
J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
Witzig TE; Geyer SM; Ghobrial I; Inwards DJ; Fonseca R; Kurtin P; Ansell SM; Luyun R; Flynn PJ; Morton RF; Dakhil SR; Gross H; Kaufmann SH
J Clin Oncol; 2005 Aug; 23(23):5347-56. PubMed ID: 15983389
[TBL] [Abstract][Full Text] [Related]
6. Temsirolimus and mantle cell lymphoma. Highly toxic, limited efficacy.
Prescrire Int; 2010 Dec; 19(111):276-8. PubMed ID: 21355378
[TBL] [Abstract][Full Text] [Related]
7. Temsirolimus for the treatment of mantle cell lymphoma.
Hess G
Expert Rev Hematol; 2009 Dec; 2(6):631-40. PubMed ID: 21082954
[TBL] [Abstract][Full Text] [Related]
8. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
Yazbeck VY; Buglio D; Georgakis GV; Li Y; Iwado E; Romaguera JE; Kondo S; Younes A
Exp Hematol; 2008 Apr; 36(4):443-50. PubMed ID: 18343280
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S
Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811
[TBL] [Abstract][Full Text] [Related]
10. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.
Boni JP; Hug B; Leister C; Sonnichsen D
Semin Oncol; 2009 Dec; 36 Suppl 3():S18-25. PubMed ID: 19963096
[TBL] [Abstract][Full Text] [Related]
11. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.
Ansell SM; Tang H; Kurtin PJ; Koenig PA; Inwards DJ; Shah K; Ziesmer SC; Feldman AL; Rao R; Gupta M; Erlichman C; Witzig TE
Lancet Oncol; 2011 Apr; 12(4):361-8. PubMed ID: 21440503
[TBL] [Abstract][Full Text] [Related]
12. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.
Ansell SM; Inwards DJ; Rowland KM; Flynn PJ; Morton RF; Moore DF; Kaufmann SH; Ghobrial I; Kurtin PJ; Maurer M; Allmer C; Witzig TE
Cancer; 2008 Aug; 113(3):508-14. PubMed ID: 18543327
[TBL] [Abstract][Full Text] [Related]
13. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
Malizzia LJ; Hsu A
Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
[TBL] [Abstract][Full Text] [Related]
14. [Adverse events associated with temsirolimus for patients with metastatic renal cell carcinoma].
Miyake H; Fujisawa M
Hinyokika Kiyo; 2012 Nov; 58(11):651-4. PubMed ID: 23254795
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.
Jurczak W; Ramanathan S; Giri P; Romano A; Mocikova H; Clancy J; Lechuga M; Casey M; Boni J; Giza A; Hess G
Leuk Lymphoma; 2018 Mar; 59(3):670-678. PubMed ID: 28768446
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
Hidalgo M; Buckner JC; Erlichman C; Pollack MS; Boni JP; Dukart G; Marshall B; Speicher L; Moore L; Rowinsky EK
Clin Cancer Res; 2006 Oct; 12(19):5755-63. PubMed ID: 17020981
[TBL] [Abstract][Full Text] [Related]
18. Temsirolimus: In relapsed and/or refractory mantle cell lymphoma.
Hoy SM; McKeage K
Drugs; 2010 Oct; 70(14):1819-29. PubMed ID: 20836575
[TBL] [Abstract][Full Text] [Related]
19. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
Dancey JE; Curiel R; Purvis J
Semin Oncol; 2009 Dec; 36 Suppl 3():S46-58. PubMed ID: 19963100
[TBL] [Abstract][Full Text] [Related]
20. Temsirolimus acts as additive with bendamustine in aggressive lymphoma.
Zoellner AK; Weiglein T; Hutter G; Zimmermann Y; Cieplik HC; Hess G; Dreyling M
Ann Hematol; 2016 Feb; 95(3):403-7. PubMed ID: 26658770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
